Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.

Acta Oncol 2015 Jul 30;54(7):993-1000. Epub 2015 Apr 30.

Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich , Munich , Germany.

Background: Drug-induced skin toxicity may correlate with treatment efficacy in cancer patients receiving chemotherapy or biological agents. The correlation of the capecitabine-associated hand-foot skin reaction (HFS) on outcome parameters in pancreatic cancer (PC) has not yet been investigated.

Methods: Within the multicentre phase III AIO-PK0104 trial, patients with confirmed advanced PC were randomly assigned to first-line treatment with either capecitabine plus erlotinib (150 mg/day, arm A) or gemcitabine plus erlotinib (150 mg/day, arm B). A cross-over to either gemcitabine (arm A) or capecitabine (arm B) was performed after failure of the first-line regimen. Data on skin toxicity were correlated with efficacy study endpoints using uni- and multivariate analyses. To control for guarantee-time bias (GTB), we focused on subgroup analyses of patients who had completed two and three or more treatment cycles.

Results: Of 281 randomised patients, skin toxicity data were available for 255 patients. Median time to capecitabine-attributed HFS was two cycles, 36 of 47 (77%) HFS events had been observed by the end of treatment cycle three. Considering HFS during first-line treatment in 101 patients treated with capecitabine for at least two cycles within the capecitabine plus erlotinib arm, time to treatment failure after first- and second-line therapy (TTF2) and overall survival (OS) both were significantly prolonged for the 44 patients (44%) with HFS compared to 57 patients without HFS (56%) (TTF2: 7.8 vs. 3.8 months, HR 0.50, p = 0.001; OS: 10.4 vs. 5.9 months, HR 0.55, p = 0.005). A subgroup analysis of 70 patients on treatment with capecitabine for at least three cycles showed similar results (TTF2: 8.3 vs. 4.4 months, HR 0.53, p = 0.010; OS: 10.4 vs. 6.7 months, HR 0.62, p = 0.056).

Conclusion: The present subgroup analysis from AIO-PK0104 suggests that HFS may serve as an independent clinical predictor for treatment outcome in capecitabine-treated patients with advanced PC.

Download full-text PDF

Source
http://www.klinikum.uni-muenchen.de/Pankreaszentrum-Muenchen
Web Search
http://www.tandfonline.com/doi/full/10.3109/0284186X.2015.10
Publisher Site
http://dx.doi.org/10.3109/0284186X.2015.1034877DOI Listing
July 2015
78 Reads

Publication Analysis

Top Keywords

skin toxicity
12
subgroup analysis
12
capecitabine erlotinib
12
patients
11
treatment
9
first-line treatment
8
pancreatic cancer
8
patients receiving
8
treatment capecitabine
8
mg/day arm
8
treatment outcome
8
ttf2 months
8
hand-foot skin
8
erlotinib 150
8
analysis aio-pk0104
8
skin reaction
8
150 mg/day
8
104 months
8
hfs
7
capecitabine
6

References

(Supplied by CrossRef)
Article in J Clin Oncol
Van Cutsem E et al.
J Clin Oncol 2001

Similar Publications